Femasys (NASDAQ:FEMY) versus Adagio Medical (NASDAQ:ADGM) Head to Head Comparison

Adagio Medical (NASDAQ:ADGM) and Femasys (NASDAQ:FEMY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk.

Profitability

This table compares Adagio Medical and Femasys’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adagio Medical	N/A	-661.85%	-73.35%
Femasys	-534.36%	-225.97%	-74.68%

Insider & Institutional Ownership

48.1% of Adagio Medical shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 7.8% of Adagio Medical shares are owned by insiders. Comparatively, 7.7% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Adagio Medical and Femasys”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagio Medical	N/A	N/A	-$25.08 million	($1.48)	-0.13
Femasys	$2.29 million	9.08	-$18.63 million	($3.53)	-0.70

Femasys has higher revenue and earnings than Adagio Medical. Femasys is trading at a lower price-to-earnings ratio than Adagio Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Adagio Medical and Femasys, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagio Medical	1	1	2	0	2.25
Femasys	1	0	3	0	2.50

Adagio Medical presently has a consensus price target of $3.50, suggesting a potential upside of 1,694.87%. Femasys has a consensus price target of $50.00, suggesting a potential upside of 1,916.13%. Given Femasys’ stronger consensus rating and higher possible upside, analysts plainly believe Femasys is more favorable than Adagio Medical.

Volatility & Risk

Adagio Medical has a beta of -0.09, indicating that its stock price is 109% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.07, indicating that its stock price is 307% less volatile than the S&P 500.

Summary

Femasys beats Adagio Medical on 7 of the 13 factors compared between the two stocks.

About Adagio Medical

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company is based in Laguna Hills, California.

About Femasys

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.